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INTroDuCTIoN
Intramammary infection (mastitis) is the most common 
reason for the use of antimicrobials in dairy cows (Mitchell 
et al. 1998; Grave et al. 1999). Antimicrobials have 
been used to treat mastitis for more than fifty years, but 
consensus about the most efficient, safe, and economical 
treatment is still lacking. The concept of evidence-based 
medicine has been introduced to veterinary medicine 
(Cockcroft and Holmes 2003) and should apply also to 
treatment of mastitis. The impact on public health should 
be taken into account as dairy cows produce milk for 
consumption (OIE 2008). The aim of this article is to review 
current treatments of mastitis during lactation and seek for 
evidence-based, best practice treatment recommendations 
for bovine mastitis.
PHArmACoKINeTIC	AND	PHArmACoDyNAmIC	
CoNSIDerATIoNS	
The bovine mammary gland is a difficult target for 
antimicrobial treatment. Penetration of substances 
into milk when administered parenterally or absorption 
and distribution throughout the udder when infused 
intramammarily (IMM) depends on their pharmacokinetic 
characteristics. These are lipid solubility, degree of 
ionization, extent of binding to serum and udder proteins, 
and the type of vehicle. Antimicrobial treatment of dairy 
cows creates residues into milk, and residue avoidance 
is an important aspect of mastitis treatment (Wagner and 
Erskine 2006).
Pharmacodynamics of the antimicrobial is another aspect 
which should be considered. Milk should not interfere 
with antimicrobial activity. The activity of macrolides, 
tetracyclines and trimethoprim-sulphonamides has been 
shown to be reduced in milk (Louhi et al. 1992; Fang 
and Pyörälä 1996). Selecting a substance with a low 
minimum inhibitory concentraton (MIC) value for the target 
pathogen is preferable, particularly when the antimicrobial 
is administered systemically. The antimicrobial should have 
bactericidal rather than bacteriostatic action, because 
phagocytosis is impaired in the mammary gland (Kehrli and 
Harp 2001). 
Antimicrobial susceptibility determined in vitro has been 
considered as a prerequisite for treatment. However, 
activity in vitro does not guarantee efficacy in vivo when 
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treating bovine mastitis. Antimicrobial resistance amongst 
mastitis pathogens has not yet emerged as a clinically 
relevant issue, but geographical regions may differ in this 
respect. The biggest problem is the widespread resistance 
of staphylococci, particularly Staphylococcus aureus, 
to penicillin G (Pitkälä et al. 2004; Olsen et al. 2006; 
Hendriksen et al. 2008). Cure rates for mastitis caused 
by penicillin-resistant strains of S. aureus seem to be 
inferior to those of mastitis due to penicillin-susceptible 
strains (Ziv and Storper 1985; Pyörälä and Pyörälä 1998; 
Sol et al. 2000; Taponen et al. 2003). It is not known if 
this is due to pharmacologic problems of the drugs used, 
or virulence factors possibly linked to β-lactamase gene of 
the resistant isolates (Haveri et al. 2005). Using an in vitro 
β-lactamase test for determining resistance to penicillin G 
of staphylococci before treatment is recommended (Olsen 
et al. 2006).
Coagulase-negative staphylococci tend to be more resistant 
than S. aureus and easily develop multiresistance (Pitkälä 
et al. 2004; Sawant et al. 2009). Mastitis causing 
streptococci have remained susceptible to penicillin G, 
but emerging resistance to macrolides and lincosamides 
has been detected (Pitkälä et al. 2004; Loch et al. 2005). 
Antimicrobial susceptibility of coliform bacteria varies but 
normally is not a limiting factor for therapy (Lehtolainen et al. 
2003; FINRES-Vet 2007; Wagner and Erskine 2006).
INTrAmAmmAry	or	SySTemIC	
ADmINISTrATIoN?
An important question regarding the treatment of mastitis 
is whether the antimicrobial should accumulate in the 
milk or in the udder tissue (Erskine 2003). The target 
site may depend on the causative agent: streptococci are 
known to remain in the milk compartment, but S. aureus 
penetrates udder tissue and causes deep infection (Table 1). 
The most common route of administration of antimicrobials 
in mastitis is the IMM route. The advantages of this 
route are high concentrations of the substance achieved 
in the milk and low consumption of the antimicrobial as 
the drug is directly infused into the diseased quarter. 
For example, concentration of penicillin G in milk after 
IMM administration is 100-1000 times as high as the 
concentration after systemic (parenteral) administration 
(Franklin et al. 1984, 1986; Ziv and Storper 1985; 
Moretain and Boisseau 1989). A disadvantage of the 
IMM administration is uneven distribution throughout the 
udder (Ullberg et al. 1958; Ehinger and Kietzmann 2000a, 
2000b) and the risk of infecting the quarter when infusing 
the product via the teat canal. Efficacy of IMM treatment 
varies according to the causative pathogen, with the best 
therapeutic response being shown for mastitis caused 
by streptococci, coagulase-negative staphylococci, and 
Corynebacterium spp..
The systemic route of administration has been suggested 
to be more efficient than IMM for the treatment of clinical 
mastitis as antimicrobials theoretically have better 
penetration of the udder tissue by this route (Ziv 1980; 
Erskine 2003). However, it is difficult to attain and maintain 
therapeutic concentrations in milk or udder tissue following 
systemic administration. Very few substances have optimal 
pharmacokinetic and pharmacodynamic characteristics for 
systemic mastitis treatment. With many commonly used 
broad-spectrum antimicrobials such as oxytetracycline, 
trimethoprim-sulphonamide and ceftiofur, it is difficult to 
produce and maintain therapeutic concentrations in the 
milk (Erskine et al. 1995; Kaartinen et al. 1999). They 
have been tested for systemic treatment and prevention 
of mastitis with poor efficacy (Erskine and Barlett 1996; 
Kaartinen et al. 1999; Duenas et al. 2001; Lents et al. 
2002). Macrolides would have ideal pharmacokinetics 
(Franklin et al. 1986; Sanders et al. 1992), but clinical 
studies have failed to demonstrate efficacy when used 
for the systemic treatment of clinical mastitis (Pyörälä 
and Pyörälä 1998; Owens et al. 1999). In streptococcal 
mastitis, spiramycin and tylosin have shown reasonable 
efficacy (Pyörälä and Pyörälä 1998; McDougall et al. 2007). 
One additional problem for the bovine practitioner is that 
the recommended dosage for many antibiotic preparations 
for adult cattle may be too low when pharmacological 
aspects are considered, but residue studies have been 
carried out using the approved dosages. Repeated 
intramuscular injections of large volumes of antibiotics can 
be irritating and cannot be recommended from the animal 
welfare point of view (Pyörälä et al. 1994b; Kaartinen et al. 
1999). 
One substance used for systemic treatment is penicillin 
G, which as a weak acid penetrates poorly into the 
mammary gland, however, due to the very low MIC values 
of susceptible organisms, therapeutic concentrations can 
be achieved in milk (Franklin et al. 1984, 1986; Ziv and 
Storper 1985). Penethamate is a more liphophilic penicillin 
G formulation and diffuses better than penicillin G procaine 
into milk (Ziv and Storper 1985). The efficacy of systemic 
treatment with penicillin G or penethamate has been shown 
in clinical trials (Jarp et al. 1989; Waage 1997; Pyörälä and 
Pyörälä 1998; McDougall et al. 2007). Combinations of 
penicillin and aminoglycosides should not be used, as there 
is no scientific evidence demonstrating a better efficacy for 
the combination (Taponen et al. 2002) and aminoglycosides 
are known to produce long-lasting residues (Jones and 
Ward 1990; Whittem and Hanlon 1997). 
The only type of mastitis where systemic treatment would 
be clearly advantageous may be mastitis caused by S. 
Milk/ducts Udder 
tissue
Cow
Streptococcus agalactiae +++ --- ---
Other streptococci +++ + ---
Staphylococcus aureus + +++ ---
Coagulase-negative staphylococci +++ --- ---
Arcanobacterium pyogenes 
(summer mastitis)
--- ++ +++
Coliforms + -- +++
Table 1: Where to target antimicrobial therapy in clinical mastitis due to different 
pathogens (Erskine 2003)Irish	Veterinary	Journal	Volume	62	Supplement 42
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aureus (Taponen et al. 2003; Barkema et al. 2006). 
In severe mastitis due to coliform bacteria, parenteral 
administration of antimicrobials has been suggested to 
combat bacteraemia (Wenz et al. 2001). The general 
benefit of antimicrobial treatment in coliform mastitis has 
been questioned (Jones et al. 1990; Pyörälä et al. 1994a), 
but systemic antimicrobial treatment is recommended 
in cases of severe Escherichia coli mastitis with heavy 
bacterial growth in the udder. Fluroquinolones and 
cefquinome have shown efficacy in experimental trials 
(Shpigel et al. 1997; Dosogne et al. 2002; Rantala et 
al. 2002; Poutrel et al. 2008) and ceftiofur in a clinical 
field trial (Erskine et al. 2002). There is no evidence that 
administering bactericidal antimicrobials to cows with 
severe coliform mastitis causes the release of massive 
amounts of endotoxin (Dosogne et al. 2002). Finally, the 
antimicrobial used for systemic treatment of mastitis must 
be approved for dairy cattle. The availability of substances 
on the market differs between countries. For example, 
penicillin G procaine or fluoroquinolones are not approved 
for dairy cattle in the United States.
TreATmeNT	oF	ClINICAl	mASTITIS	IN	
PrACTICe
Treatment of mastitis should be targeted towards the 
causative bacteria whenever possible, but in acute 
situations, treatment is initiated based on herd data and 
personal experience. Rapid or on-farm bacteriological 
diagnosis would facilitate the selection of the most 
appropriate antimicrobial. Treatment protocols and drug 
selection for each farm should be made by veterinarians 
familiar with the farm (Sawant et al. 2005; Wagner and 
Erskine 2006). The use of on-farm written protocols 
for mastitis treatment can promote judicious use of 
antimicrobials (Raymond et al. 2006; Passantino 2007). 
Therapeutic response of the cows can be monitored using 
individual somatic cell count data if available, or using the 
California Mastitis Test, and with bacteriological samples in 
herds with contagious mastitis.
In general, the use of narrow-spectrum antimicrobials 
is preferable (Table 2). Prudent use guidelines have been 
developed which also include antimicrobial treatment 
of mastitis (Anon 2003; Passantino 2007). First choice 
antimicrobials for treating mastitis caused by streptococci 
and penicillin-susceptible staphylococci are β-lactam 
antimicrobials, particularly penicillin G. Broad-spectrum 
antimicrobials such as third or fourth generation 
cephalosporins should not be used as first alternatives 
for mastitis, as they may increase emergence of broad-
spectrum β-lactam resistance. Systemic treatment is 
recommended in clinical mastitis due to S. aureus and in 
severe cases of coliform mastitis, preferably in combination 
with IMM treatment (Barkema et al. 2006). Too short a 
duration of standard treatment is probably an important 
reason for poor cure rates in mastitis therapy. A longer 
treatment improves cure rates, and duration of treatment 
should generally be extended in mastitis caused by S. 
aureus and Streptococcus uberis (Pyörälä and Pyörälä 
1998; Oliver et al. 2004; Deluyker et al. 2005). Clinical 
mastitis should be treated for at least three days; this 
recommended treatment duration is longer than label 
treatments in many countries. All mastitis treatment should 
be evidence based i.e., the efficacy of each product and 
treatment length should be demonstrated by scientific 
studies (Cockcroft and Holmes 2003). 
SuBClINICAl	mASTITIS
Treating subclinical mastitis with antimicrobials is generally 
not economical during lactation because of high treatment 
costs and poor efficacy. In a study with a large number of 
subclinical mastitis cases (Wilson et al. 1999), the overall 
bacteriological cure rate for antimicrobial treatment was 
75% and that for no treatment 68%. The marginal benefit 
applied for streptococcal mastitis only; in mastitis due 
to S. aureus, antimicrobials were equal to no treatment. 
Treatment of subclinical mastitis will not affect the 
incidence of mastitis in the herd unless other preventive 
measures are taken. Studies on treating cows based on 
high somatic cell counts have generally shown that no 
effect on milk production has been achieved (McDermott 
et al. 1983; Shephard et al. 2000, Hallén Sandgren et al. 
2008) In herd problems caused by very contagious bacteria 
such as S. aureus or Streptococcus agalactiae treatment of 
subclinical mastitis is advised (Wagner and Erskine 2006). 
Table 2: Suggestions for antimicrobial treatment of clinical mastitis due to different pathogens. The availability of substance on the market mentioned in the table may 
differ between countries
Micro-organism Species Drug of choice Alternative Comments
Streptococci Streptococcus agalactiae
Streptococcus dysgalactiae
Streptococcus uberis
Enterococci
Penicillin G
According to 
susceptibility testing
IMM treatment preferable. 
Prognosis for bacteriological cure is poor
Staphylococci Staphylococcus aureus
Coagulase negative staphylococci
ß-lactamase -ve
Staphylococcus aureus
Coagulase negative staphylococci
ß-lactamase +ve
Penicillin G
No antimicrobials  Cloxacillin Macrolides 
Lincosamides 
Combination treatment in S. aureus mastitis
IMM and/or systemic treatment depending on the  drug 
used. Prognosis for S. aureus mastitis is poor. Cloxacillin 
may select for methicillin-resistant 
Coliforms Escherichia coli
Klebsiella spp.
No antimicrobials Fluoroquinolones
Cephalosporins 
Antimicrobials necessary in serious cases and during 
puerperal periodIrish	Veterinary	Journal	Volume	62	Supplement
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